These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21449154)

  • 1. [Vaccination against human papilloma virus and cervical cancer].
    Kidon MI; Shechter E; Toubi E
    Harefuah; 2011 Jan; 150(1):33-6, 68. PubMed ID: 21449154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diseases caused by human papilloma viruses].
    Zollner U; Schwarz TF
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current prophylactic HPV vaccines and gynecologic premalignancies.
    Harper DM
    Curr Opin Obstet Gynecol; 2009 Dec; 21(6):457-64. PubMed ID: 19923989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
    Schwarz TF
    Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.
    McKeage K; Romanowski B
    Drugs; 2011 Mar; 71(4):465-88. PubMed ID: 21395359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K; Romanowski B
    BioDrugs; 2011 Aug; 25(4):265-9. PubMed ID: 21815703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV vaccines - A review of the first decade.
    Harper DM; DeMars LR
    Gynecol Oncol; 2017 Jul; 146(1):196-204. PubMed ID: 28442134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Currently approved prophylactic HPV vaccines.
    Harper DM
    Expert Rev Vaccines; 2009 Dec; 8(12):1663-79. PubMed ID: 19943762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus and vaccination in cervical cancer.
    Wang KL
    Taiwan J Obstet Gynecol; 2007 Dec; 46(4):352-62. PubMed ID: 18182340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HPV vaccination and cervical cancer.
    Szarewski A
    Curr Oncol Rep; 2012 Dec; 14(6):559-67. PubMed ID: 22890794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
    Du J; Ährlund-Richter A; Näsman A; Dalianis T
    Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress on the differences between T and B cell responses to three different forms of human papilloma virus (HPV) vaccination].
    Peng Q; Li Y; Li J; Yao X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):378-382. PubMed ID: 38710522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
    Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
    J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL; Joura EA
    Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer.
    Tjalma WA; Arbyn M; Paavonen J; van Waes TR; Bogers JJ
    Int J Gynecol Cancer; 2004; 14(5):751-61. PubMed ID: 15361181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.